Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Pfizer stock has suffered as demand for the company’s top selling coronavirus products declined. The pharma giant has reached an important transition point. Right now, as an investor, you may be ...

As well as, falling in tandem with the release of Pfizer’s annual earnings report, which reflected revenues of $63.6 billion. In the announcement, Bourla stated: “I’m excited for what’s ...

Pfizer's Q4 2024 earnings beat expectations, but the stock fell due to disappointing 2025 guidance and concerns over patent expirations. Despite a 6.7% revenue increase in 2024, Pfizer's 2025 ...

(Reuters) -Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as it aims to show investors steadier execution and growth after ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance (5) provided on December 17 ...

Pfizer's Q4 revenue beats expectations with $17.8 billion; EPS also beats Cost-cutting measures to save Pfizer $4.5 billion by year-end Analysts shift focus to Pfizer's future drug pipeline and ...